| Issuer | % of Class | Filed |
|---|---|---|
|
CytoMed Therapeutics Ltd
13G/A
Amendment 3
GDTC · Y1R80M106
|
10.0% |
10/23/2026
Event 10/12/2026
|
|
CytoMed Therapeutics Ltd
13G/A
Amendment 2
GDTC · Y1R80M106
|
11.3% |
3/24/2025
Event 12/16/2024
|
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.